Aevi Genomic Medicine, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced operating loss was USD 4.042 million compared to USD 7.299 million a year ago. Net loss was USD 4.042 million compared to USD 7.249 million a year ago. Basic loss per share was USD 0.06 compared to USD 0.12 a year ago. For the nine months, operating loss was USD 12.545 million compared to USD 24.285 million a year ago. Net loss was USD 12.526 million compared to USD 24.149 million a year ago. Basic loss per share was USD 0.19 compared to USD 0.4 a year ago.